Claresa Levetan, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1063483469
Payments from drug & device makers
Across 328 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$793
- Abbott$614
- Mannkind Corporation$351
- Medtronic$333
- Amgen$293
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,55699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $1,033 |
| Novo Nordisk | 56 | $793 |
| Abbott | 36 | $614 |
| Mannkind Corporation | 16 | $351 |
| Medtronic | 22 | $333 |
| Amgen | 15 | $293 |
| Corcept Therapeutics | 15 | $265 |
| Amarin Pharma, Inc. | 10 | $196 |
| Novartis | 10 | $194 |
| AbbVie | 9 | $166 |
| Xeris Pharmaceuticals, Inc. | 8 | $133 |
| Sanofi-aventis U.S. LLC | 7 | $129 |
| AstraZeneca(2 entities) | 8 | $124 |
| Kyowa Kirin, Inc. | 6 | $120 |
| Recordati_rare_diseases_inc. | 6 | $100 |
| Insulet Corporation | 5 | $94 |
| Esperion Therapeutics, Inc. | 4 | $85 |
| Tandem Diabetes Care, Inc. | 4 | $75 |
| Ascendis Pharma Endocrinology Inc | 3 | $66 |
| Ascensia Diabetes Care US Inc. | 3 | $65 |
| Sequel Med Tech, LLC | 2 | $63 |
| Dexcom, Inc. | 3 | $50 |
| BETA Bionics, Inc. | 3 | $49 |
| Cequr Corporation | 3 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Coloplast | 1 | $26 |
| IBSA Pharma Inc. | 1 | $25 |
| BD | 1 | $18 |
| Vistapharm, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$5,606 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 302 | $337,052 |
| OzempicSemaglutide | 250 | $303,229 |
| Tresiba Flextouch U-100Insulin Degludec | 185 | $114,464 |
| JardianceEmpagliflozin | 105 | $94,259 |
| Tresiba Flextouch U-200Insulin Degludec | 94 | $70,189 |
| TrulicityDulaglutide | 52 | $68,471 |
| Novolog FlexpenInsulin Aspart | 202 | $46,353 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $30,512 |
| RybelsusSemaglutide | 22 | $28,541 |
| JanuviaSitagliptin Phosphate | 27 | $26,746 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 283 | $24,417 |
| Teriparatide | 11 | $14,296 |
| FarxigaDapagliflozin Propanediol | 14 | $13,685 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $13,142 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $12,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,033 | $408,675366 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $793 | $341,507307 claims |
| AstraZenecaFarxiga | $124 | $13,68514 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $129 | $12,59711 claims |
| AbbVieSynthroid | $166 | $12,244188 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $38 | $3,159399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Intekhab AhmedPhiladelphia$926K
- Jane MayrinPhiladelphia$628K
- Michael RickelsPhiladelphia$606K
- Steven NagelbergPhiladelphia$483K
- Kevin WilliamsPhiladelphia$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.